Fadraciclib
Near Add Your Location
Not currently accepting
A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)
- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
- Phase 1/2